Employers aren’t expanding coverage of GLP-1 obesity drugs: survey
A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news…
Medicare obesity drug GLP-1 coverage starting July 1
Millions of older Americans in Medicare are about to receive a benefit that has never existed before: coverage…
Medicare obesity drugs: Walmart, CVS step in to help seniors
A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news…
Eli Lilly, Regeneron in FDA PreCheck manufacturing program
Eli Lilly and Regeneron are among the first seven companies the U.S. Food and Drug Administration selected for…
The AI trade cooled and oil sank. A closer look at Wall Street’s volatile week
Wall Street spent the week debating who the biggest winners and losers of the artificial intelligence boom will…
GLP-1 weight loss pills may be bad thing for job insurance coverage
The new GLP-1 pills are likely to boost consumer demand for these popular weight-loss drugs. But it could…
We’re trimming a stock into strength, raising our price target
We are selling 50 shares of Cardinal Health at roughly $235. Following the trade, Jim Cramer’s Charitable Trust…
Space race comes for pharma: Why drug development is heading to orbit
The highly anticipated SpaceX mega-IPO is part of a space frenzy that is moving beyond satellite connectivity, launch…
Novo Nordisk, Eli Lilly roll out obesity pills, prepare for Medicare coverage
Novo Nordisk and Eli Lilly took their GLP-1 pill battle to the preeminent obesity meeting this weekend as…
Eli Lilly makes a new push into vaccines – here’s what to know
The Eli Lilly logo appears on the company’s office in San Diego, California, Nov. 21, 2025. Mike Blake…
Eli Lilly lawsuit says rebate fraud tied to Pentecostal church leaders
Eli Lilly says it has uncovered a long-running scheme to steal more than $200 million in rebates from…
Biogen Alzheimer’s drug moves to late stage trial
A Biogen facility in Cambridge, Massachusetts. Brian Snyder | Reuters Biogen plans to advance an experimental drug for…